Physician profile
James Anderson
NPI 1689671802
$18,139.23
in general payments reported to CMS, 2019-2025
60 companies · $3,296 in 2025
The $3,296 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $1,678 · 2021: $2,650 · 2022: $3,187 · 2023: $3,297 · 2024: $2,883 · 2025: $3,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,360 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,359.99 |
| Education | $116.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,364.99 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Neurocrine Biosciences, INC. | $1,315.59 | 2019-2025 | Ingrezza |
| Sk Life Science, INC. | $1,272.79 | 2020-2025 | Xcopri |
| Biogen, INC. | $1,235.69 | 2019-2025 | Vumerity, Plegridy, Avonex |
| Lilly USA, LLC | $1,187.53 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Lundbeck LLC | $1,051.84 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $880.36 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Argenx US, INC. | $837.27 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $832.40 | 2019-2025 | |
| Mdd US Operations, LLC | $815.98 | 2019-2024 | Gocovri |
| Csl Behring | $791.57 | 2019-2025 | Hizentra |
| Pfizer INC. | $695.30 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $458.48 | 2019-2022 | |
| Amgen INC. | $439.67 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $367.65 | 2022-2023 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.